Erlotinib in the Treatment of Non-small Cell Lung Cancer: Current Status and Future Developments

摘要: Erlotinib is an orally small molecule inhibiting the tyrosine kinase activity of epidermal growth factor receptor (EGFR). Currently, erlotinib, at a standard oral daily dose 150 mg, licensed for treatment unselected recurrent non-small cell lung cancer (NSCLC) patients, however, it being investigated in all stages NSCLC. well tolerated, with common toxicities including rash and diarrhoea. The optimization therapeutic impact erlotinib NSCLC will be more defined when reliable predictive factors are identified. An important step has been made molecular characterization potentially sensitive patients. In fact, we have learned that activation, somatic EGFR gene mutations within domain, associated high possibility long lasting response to erlotinib. present review discusses role Non-small accounts about 85% diagnoses (1). majority people diagnosed unsuitable surgery since most patients advanced disease diagnosis. recent decades, conventional treatments (surgery, chemotherapy, radiotherapy) apparently reached plateau effectiveness improving outcomes which still remain disappointing, especially (2), hence new approaches developed. (EGFR) one studied targets therapy. anti-EGFR inhibitor (TKI), Epidermal Growth Factor Receptor Pathway